Hilda Li

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, on its private placement financing of up to $150 million.

Cooley advised Summit Healthcare Acquisition Corp. (Summit Healthcare), a publicly traded special purpose acquisition company, on its business combination with YishengBio Co., Ltd. (YS Biopharma), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of innovative vaccines and therapeutic biologics.

Cooley advised J.P. Morgan, Morgan Stanley, UBS and Evercore as part of Grab’s agreement to merge with Altimeter Capital’s special purpose acquisition company or SPAC. The transaction marks the largest SPAC merger in history and values the SoftBank-backed technology company at approximately $40 billion. Will Cai in Hong Kong and Ferish Patel in Singapore led a global team of Cooley lawyers across Hong Kong, Singapore and the US on the transaction.